Akihiko Asahina - Concepedia

Author

Akihiko Asahina

Also Known As

A ASAHINA, A Asahina, A. Asahina, A., Asahina, AKIHIKO ASAHINA, Akihiko ASAHINA, Akihiko Asahina, Hironobu Ihn, Noriko Arase

335

Publications

7.3K

Citations

H-Index

110

Concepts

All Affiliations

The University of Tokyo Jikei University School of Medicine National Sagamihara Hospital Fukushima Medical University Jichi Medical University

About

Akihiko Asahina is an author at The University of Tokyo specializing in medicine, immunology, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	53	3.7K
2	Allergy	6	6	392
3	Natural Sciences	2	2	38
4	Allergy Medicine	2	2	42
5	Biochemistry	1	1	21

Akihiko Asahina

110

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide Junichi Hosoi, Gëorge F. Murphy, Christine Egan, Nature Langerhans Cell FunctionNeuropeptidesMolecular PhysiologyMolecular NeuroscienceSignal Transduction	1993	617
Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity Takashi Kakinuma, Koichiro Nakamura, Motoshi Wakugawa, Journal of Allergy and Clinical Immunology InflammationAtopic DermatitisSerum ThymusImmunologyImmune Regulation	2001	563
Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris Yuichiro Tsunemi, Hidehisa Saeki, Koichiro Nakamura, Journal of Dermatological Science InflammationInterleukin-12 P40 GeneAtopic DermatitisImmunologyClinical Dermatology	2002	189
IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. Stefan Beissert, Junichi Hosoi, Stephan Grabbe, The Journal of Immunology Epidermal Antigen-presenting CellsImmunologyImmune RegulationImmunoeditingImmunologic Mechanism	1995	187
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study Akihiko Asahina, Hidemi Nakagawa, Takafumi Etoh, The Journal of Dermatology	2010	181
Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris Takashi Kakinuma, Hidehisa Saeki, Yuichiro Tsunemi, Journal of Allergy and Clinical Immunology InflammationAtopic DermatitisImmune RegulationImmunologyClinical Dermatology	2003	155
Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis Takashi Kakinuma, Kentaro Nakamura, Motoshi Wakugawa, Clinical & Experimental Immunology	2002	154
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) Joseph F. Merola, Robert Landewé, Iain B. McInnes, The Lancet	2022	149
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) Iain B. McInnes, Akihiko Asahina, Laura C. Coates, The Lancet	2022	146
Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. Akihiko Asahina, Junichi Hosoi, Stefan Beissert, The Journal of Immunology Cgrp AdministrationImmunologyMolecular BiologyPeptide ScienceDermatology	1995	131

Page 1